This website is best viewed using the vertical display on your mobile device.
INDICATIONS
SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with:
SPRYCEL® is indicated for the treatment of pediatric patients 1 year of age and older with:
cCCyR† rates vs imatinib by Year 1 and Year 51
Dasatinib does not appear to be active against the T315I mutation, based on in vitro data.1
In newly diagnosed chronic phase CML patients:
cCCyR=confirmed complete cytogenetic response; CI=confidence interval; MMR=major molecular response.
*Inclusive of cCCyR in newly diagnosed adult patients with CP Ph+ CML by 1 and 5 years.
†Confirmed CCyR (cCCyR) was defined as CCyR (0% Ph+ metaphases) on 2 consecutive occasions at least 28 days apart.1,2
‡Adjusted for Hasford score and indicated statistical significance at a predefined nominal level of significance.1
||MMR (at any time) defined as BCR-ABL ratios of ≤0.1% by RQ-PCR in peripheral blood samples standardized on the International Scale. These are cumulative rates representing minimum follow-up for the time frame specified.1
References: